Jin Medical International Ltd. has successfully regained compliance with Nasdaq's periodic filing requirements after submitting its annual report for the fiscal year 2023. The company had previously received a notice from Nasdaq on March 28, 2024, stating that it must file the report by May 20, 2024, to maintain its listing. The annual report was filed on April 26, 2024, and on May 9, 2024, Nasdaq confirmed the company's compliance. However, Nasdaq will continue to monitor Jin Medical International's adherence to the filing rule until May 9, 2025, and any future non-compliance during this period will lead directly to a delisting determination without the opportunity for the company to submit a new compliance plan.

Jin Medical International Ltd. has successfully regained compliance with Nasdaq's periodic filing requirements after submitting its annual report for the fiscal year 2023. The company had previously received a notice from Nasdaq on March 28, 2024, stating that it must file the report by May 20, 2024, to maintain its listing. The annual report was filed on April 26, 2024, and on May 9, 2024, Nasdaq confirmed the company's compliance. However, Nasdaq will continue to monitor Jin Medical International's adherence to the filing rule until May 9, 2025, and any future non-compliance during this period will lead directly to a delisting determination without the opportunity for the company to submit a new compliance plan.